There were three posters from the ABCD audit programme presented at the Diabetes UK annual professional conference at SEC, Glasgow, 26-28 February 2025.

In a poster from the Worldwide Audit of Testosterone Deficiency in Men with Type 2 Diabetes, Prof Hugh Jones showed that testosterone replacement therapy (TRT) improved symptoms and quality of life increasingly over at least 24 months. TRT also reduced HbA1c increasingly over a three year follow up period.

Join us for this valuable face to face conference as we focus on all things inpatient diabetes, taking place on 13th June in Liverpool.

Hear from our expert speakers who will provide in-depth insight and inform participants about the latest developments in how to introduce the latest innovations in inpatient diabetes care. 

By attending the conference, you will: 

Effectiveness of Semaglutide in Oral vs Subcutaneous Injectable Formulation: An analysis of UK Real-world Data in the Association of British Clinical Diabetologists (ABCD) national audit

Endoscopic Duodenal-jejunal Bypass Liner treatment for Type 2 Diabetes and Obesity: A comparison of the outcomes with an implantation period of 6 months versus 12 months in a worldwide registry 

Testosterone therapy improves quality of life and sexual health replacement in hypogonadal men with type 2 diabetes - the ABCD Worldwide Audit

Do you have any experience of patients with type 1 diabetes who are on Afrezza (inhaled insulin) long-term?

ABCD has been contacted by Professor Colin Dayan who would be interested to know how well it is tolerated. Please contact Prof Dayan directly on dayancm@cardiff.ac.uk to share any insights or experience you may have.